The new product is a type of intramedullary nail, which is a rod that is inserted into a badly broken bone to keep the fragments together, according to the report.
The FDA clearance means that the agency feels that this device is similar to other products on the market and does not require clinical trials.
Read the Commercial Appeal’s report about NovaLign’s new intramedullary nail.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
